MedTrace Logo

A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

NCT02998047 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2022-03-08

No results posted yet for this study

Summary

1. Establish the MTD of Lintuzumab-Ac225 as monotherapy
2. Establish overall response rate (ORR) where ORR = CR + sCR+ VGPR+PR)
3. Confirm the safety profile of the treatment regimen
4. Estimate progression-free survival (PFS) and overall survival

Conditions

  • Refractory Multiple Myeloma

Interventions

DRUG

Lintuzumab AC 225

Lintuzumab-Ac225 is an immunoconjugate \[antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)\] for the treatment of multiple myeloma.

Sponsors & Collaborators

  • Actinium Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Avinash Desai, MD · Actinium Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2020-05-31
Completion
2020-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02998047 on ClinicalTrials.gov